In a recent NAFTA Investor-State claim brought against the United States by Apotex Inc., Canada’s largest producer of generic drugs, the Tribunal upheld the US’ preliminary objections to jurisdiction on the grounds that the company’s efforts to win approval for generic drugs in the US market did not make it an "investor" under NAFTA Chapter Eleven.